Jiuzi Hldgsの空売り状況は、投資家がJiuzi Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Jiuzi Hldgs (NASDAQ:JZXN) 株価情報, 空売り情報

Jiuzi Hldgs

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.

Jiuzi Holdings Inc

Wells Fargo analyst Edward Kelly maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Overweight and raises the price target from $70 to $73.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Kroger, Raises Price Target to $73

Trading Ideas

SFHG

Samfine Creation Holdings Shares Resumed Trade

Wells Fargo analyst Zachary Fadem maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and raises the price target from $67 to $75.

Wells Fargo Maintains Overweight on Chipotle Mexican Grill, Raises Price Target to $75

APVO

Aptevo Therapeutics Inc. Shares Resumed Trade

On Thursday, Trevi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing&nbsp;Phase&nbsp;2b&nbsp;CORAL trial&nbsp;in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42458078/trevi-therapeutics-announces-positive-outcome-from-sample-size-re-estimation-resulting-in-no-chang" rel="noreferrer noopener">sample size for the trial (N=160)</a>.
The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with chronic cough.
The primary efficacy endpoint for the trial is the relative change in 24-hour cough frequency at the end of Week 6 versus baseline for Haduvio compared to placebo, as measured with an objective cough monitor (VitaloJAK). The trial will also explore secondary endpoints, including patient-reported outcome measures for cough.
The trial has reached 75% of the targeted enrollment,&nbsp;and topline results from the full trial continue to be expected in the first half of 2025.
The SSRE analysis was conducted on the highest dose (108mg twice daily) in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment.
Based on the SSRE analysis, it was recommended that the CORAL trial should continue as planned to maintain the pre-specified conditional power of 80% or greater.
The other two potential pre-specified outcomes of the SSRE analysis were increased sample size or futility.
&#8220;We are pleased that the SSRE outcome supports the continued execution of the CORAL trial with the total number of patients as originally planned,&#8221; said&nbsp;Jennifer Good, President and CEO of Trevi Therapeutics. &#8220;This positive SSRE outcome is reassuring and confirms the key powering assumptions of the trial design. We believe this is additional confirmation of the strong efficacy observed in the Phase 2a CANAL trial in IPF cough&#8230;&#8221;
Price Action: At last check Thursday, TRVI stock was up 71.50% at $4.27.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42460099/us-listed-chinese-stocks-give-up-gains-in-anticipation-of-more-stimulus-to-beat-us-tariffs" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Give Up Gains In Anticipation Of More Stimulus</a></li>
</ul>

Biotech

Health Care

Movers

General

TRVI

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Wells Fargo analyst Ike Boruchow maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Equal-Weight and raises the price target from $38 to $42.

BBWI

Wells Fargo Maintains Equal-Weight on Bath & Body Works, Raises Price Target to $42

WIIM

CELH

Celsius Holdings shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and a $37 price target.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Deutsche Bank analyst Steve Powers initiated coverage on Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Hold rating and announced a price target of $81. Lamb Weston shares closed at $74.96 on Wednesday. <a href="https://www.benzinga.com/quote/LW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer analyst Kristen Owen initiated coverage on CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) with an Outperform rating and announced a price target of $114. CF Industries shares closed at $89.82 on Wednesday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Michael Funk initiated coverage on Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) with a Buy rating and announced a price target of $40. Box shares closed at $32.27 on Wednesday. See how other analysts view this stock.</li>
<li>Macquarie analyst Steve Koenig initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with an Outperform rating and announced a price target of $380. Autodesk shares closed at $307.46 on Wednesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Steve Koenig initiated coverage on MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Neutral rating and announced a price target of $300. MongoDB shares closed at 297.20 on Wednesday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-1024x622.png" alt="" class="wp-image-689605" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/12094240/image-103.png 1083w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>

Initiation

Markets

ADSK

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Homebuyers should brace for another year of elevated mortgage rates, with Realtor.com forecasting an average of 6.3% next year. While down from 2024&#8217;s projected 6.7% average, rates will remain well above the 4% historical average from 2013 to 2019.
The silver lining is the expanding housing inventory, which Realtor.com projects to grow by 11.7% in 2025, according to the report. New construction will add to supply, with housing starts expected to jump 13.8% to 1.1 million units.&nbsp;
Don't Miss:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<a href="https://www.benzinga.com/real-estate/reit/24/12/42316081/5-housing-market-trends-for-2025-what-zillows-forecast-means-for-you">After years of tight inventory</a>, the improvements could create more breathing room for buyers.
&#8220;This past year brought us a surprising upward trend in home price growth despite the persistence of high mortgage rates and rising inventory,&#8221; Realtor.com&#8217;s economists noted in their forecast. Home prices are expected to climb an additional 3.7% in 2025, following 2024&#8217;s projected 4% increase.
According to the forecast, the brief dip in mortgage rates to near 6% in September likely won&#8217;t return. &#8220;There will be volatility around this average, so shoppers may catch a lucky break, but our advice is to plan and budget for the mid-6% range.&#8221;
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Some markets already show signs of shifting power dynamics. About 20% <a href="https://www.benzinga.com/real-estate/24/10/41541572/purely-supply-demand-imbalance-5-u-s-cities-with-homes-still-under-300k">of listings nationwide had price reductions</a>, with Midwestern cities leading the trend. Cincinnati, Indianapolis and several markets across Ohio, Indiana and Illinois top the list for price cuts, led by Urbana, Ohio, where 71% of listings saw reductions.
Sales volume should tick up modestly, with existing home sales projected at 4.07 million – a 1.5% gain from this year but still well below the 2013-2019 average of 5.28 million. The report said that affordability challenges remain, though wage growth and tax adjustments could offer some relief.
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
For renters, 2025 might bring slight relief. The Realtor.com forecast projects a 0.1% decrease in asking rents, continuing 2024&#8217;s 0.2% decline. New multifamily construction should boost supply, particularly in the South, where rental stock is expected to grow 1.5% annually – the highest regional rate nationwide.
&#8220;While the rental vacancy rate is at its highest level since the start of the pandemic, it remains somewhat below the 7.2% average seen from 2013 to 2019,&#8221; the report said, suggesting continued normalization of the rental market throughout the next year.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

'Plan And Budget For The Mid-6% Range': What Homebuyers Can Expect In 2025 According To Realtor.com

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 29.88% on an annualized basis producing an average annual return of 43.55%. Currently, Vistra has a market capitalization of $49.65 billion. 
Buying $1000 In VST: If an investor had bought $1000 of VST stock 5 years ago, it would be worth $6,020.01 today based on a price of $145.94 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734014712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Overweight rating and announces Price Target of $37.

XNCR

Wells Fargo Initiates Coverage On Xencor with Overweight Rating, Announces Price Target of $37

Samfine Creation Holdings Group Shares Halted To The Downside, Stock Now Down -55.7%

Macquarie analyst Gautam Chhugani reiterates MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and maintains $600 price target.

Reiteration

MSTR

Macquarie Reiterates Outperform on MicroStrategy, Maintains $600 Price Target

Aptevo Therapeutics Shares Halted; Stock Now Up 23.4%

Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares are trading lower Thursday after the company announced a public offering by a selling stockholder and a&nbsp;<a href="https://www.benzinga.com/pressreleases/24/12/b42448132/chewy-inc-announces-public-offering-of-class-a-common-stock-by-selling-stockholder-and-concurrent-" target="_blank" rel="noreferrer noopener">concurrent share repurchase</a>.
What To Know:&nbsp;Chewy announced an underwritten public offering of 15,852,886 shares&nbsp;of its common stock, being sold by an entity affiliated with Chewy's largest shareholder&nbsp;BC Partners Advisors. The selling stockholder plans to grant the underwriters a 30-day option to purchase up to an additional 2,377,932 shares of Chewy common stock. 
Chewy will not sell any shares in the offering, and will not receive any proceeds. 
In addition, Chewy has agreed to repurchase and retire $50 million of its common stock at the same price paid by the underwriters in the offering. The concurrent repurchase is being executed separately from the company&#8217;s existing $500 million share repurchase program that was authorized in May.
The offering comes after Chewy reported mixed quarterly results last week, beating on earnings but missing on revenue. The company guided for fourth-quarter revenue of $3.18 billion to $3.2 billion versus estimates of $3.17 billion.
Following the company&#8217;s quarterly results, Goldman Sachs lifted its&nbsp;<a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noreferrer noopener">price target</a>&nbsp;to $40, RBC Capital raised its target to $42 and JPMorgan maintained an Overweight rating and moved its price target up to $38.
Chewy shares are up approximately 37% year-to-date. The rally in the online pet retailer's stock accelerated over the summer after meme stock trader&nbsp;Keith Gill,&nbsp;also known as&nbsp;"Roaring Kitty,"&nbsp;announced a stake in the company. Gill has since announced that he <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">sold his entire stake</a> in Chewy. 
See Also: <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">Producer Inflation Rises More Than Expected To 3% In November: All Eyes On The Fed&#8217;s Interest Rate Call</a>
CHWY Price Action: <a href="http://benzinga.com/quote/chwy">Chewy shares</a> were down 2.8% at $31.63 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Chewy.

Offerings

CHWY

What's Going On With Chewy Stock Thursday?

Samfine Creation Holdings Group Shares Resumed Trade

Aptevo Therapeutics Shares Resumed Trade

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment.
Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals.
The collaboration <a target="_blank" href="https://www.prnewswire.com/news-releases/ro-works-with-lilly-to-streamline-patient-access-to-authentic-zepbound-single-dose-vials-by-integrating-with-lillys-pharmacy-channel-302328012.html" rel="noreferrer noopener">integrates</a> diagnosis, prescription, and home delivery into one platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility" rel="noreferrer noopener">Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility</a>
Eli Lilly's executive vice president, Patrik Jonsson, emphasized the importance of affordability and accessibility in obesity care, noting that Zepbound's lower-cost vials represent a significant step toward breaking down barriers. "Our goal is to provide safe and effective treatment options that patients can trust," Jonsson stated.
"Lilly's release of Zepbound single-dose vials at a lower, self-pay-only price was groundbreaking and reflects the patient-centric model upon which Ro was founded. This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home," said&nbsp;Zach Reitano, co-founder &amp; CEO of Ro.
CNBC <a target="_blank" href="https://www.cnbc.com/2024/12/11/ro-to-offer-weight-loss-drug-zepbound-vials-by-working-with-eli-lilly.html" rel="noreferrer noopener">notes</a> that the collaboration enables eligible patients to access Zepbound through a "complete end-to-end" experience. Patients can receive a diagnosis, obtain a prescription, and have the medication delivered directly to their homes via Gifthealth, a digital pharmacy partnered with LillyDirect.
Zepbound vials are cash-pay products priced at $399 for a 2.5 mg dose and $549 for a 5 mg dose.
Ro also provides extensive ongoing support for weight management, including personalized care plans, 24/7 access to licensed physicians, coaching, and tools for monitoring progress.
Using data, the <a target="_blank" href="https://ro.co/weight-loss/zepbound/#faq" rel="noreferrer noopener">platform </a>helps patients choose the most cost-effective medication, whether through insurance or cash payment.
Ro additionally assists with prescriptions for Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) rival drug, Wegovy (semaglutide), and compounded alternatives.
Last week, Eli Lilly revealed topline data from the SURMOUNT-5 phase 3b trial of Zepbound (tirzepatide) compared with Novo Nordisk's Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities.
Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average,&nbsp;Zepbound led to a superior weight loss of 20.2% compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42316929/eli-lillys-zepbound-vs-novo-nordisks-wegovy-which-shows-greater-weight-loss" rel="noreferrer noopener">13.7% with Wegovy</a>.
Price Action: At last check Thursday, LLY stock was up 0.31% at $798.50.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42456428/kroger-and-albertsons-call-off-merger-plans-75-billion-share-buyback-cancels-47-billion-merger-debt" target="_blank" rel="noreferrer noopener">Kroger's $7.5 Billion Buyback Blitz: Eyes Lower Grocery Prices And Big Returns After Albertsons Pivot</a></li>
</ul>
Photo Source: Eli Lilly and Company

Large Cap

Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound

Rezolve AI Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares are trading higher Thursday after the company announced plans to align with <a href="https://www.benzinga.com/pressreleases/24/12/g42458772/rezolve-ai-aligns-with-planned-department-of-government-efficiency-doge-initiatives-to-transform-r">Department of Government Efficiency (D.O.G.E.) initiatives</a>. 
What Happened: Rezolve AI announced its active participation in initiatives expected to align with the planned presidential advisory commission D.O.G.E.
The company said its BRAiNPOWA LLM and BRAiN Commerce platform are driving retail transformation through improved operational efficiency and noted that it believes its solutions are well-positioned to support the goals of D.O.G.E.
&#8220;Efficiency and innovation go hand in hand. By embracing the principles we expect the Department of Government Efficiency to champion, we are showcasing how artificial intelligence can revolutionize retail operations while empowering a leaner and more agile workforce,&#8221; said Daniel Wagner, CEO of Rezolve AI.
Key components of Rezolve AI&#8217;s &#8220;alignment&#8221; include streamlined operations, workforce optimization, innovative payment solutions, sustainability goals and enhanced accessibility.
See Also: <a href="https://www.benzinga.com/24/12/42453807/spacex-hits-350-billion-valuation-in-insider-share-sale-ceo-elon-musk-says-no-investors-wanted-to-sell-shares">SpaceX Hits $350 Billion Valuation In Insider Share Sale: CEO Elon Musk Says &#8216;No Investors Wanted To Sell Shares&#8217;</a>
<h3 class="wp-block-heading">How To Buy RZLV Stock</h3>
By now you're likely curious about how to participate in the market for Rezolve AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Rezolve AI, which is trading at $1.99 as of publishing time, $100 would buy you 50.25 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RZLV Price Action: <a href="http://benzinga.com/quote/rzlv">Rezolve AI shares</a> were up 9.55% at $2.18 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

RZLV

What's Going On With Rezolve AI Stock Thursday?

Wells Fargo analyst Michael Brown upgrades Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) from Equal-Weight to Overweight and raises the price target from $176 to $212.

Upgrades

ARES

Wells Fargo Upgrades Ares Management to Overweight, Raises Price Target to $212

Jiuzi Holdings enters into non-binding LOI for Shenzhen Maigesong acquisition

LE and DOGZ among Consumer Discretionary movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!



Moving stocks this morning are strong early morning trading, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>HWH International (NASDAQ:<a href="https://investorplace.com/stock-quotes/hwh-stock-quote/">HWH</a>) stock is rocketing more than 85% with strong early morning trading.</li>



<li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) shares are soaring over 50% with heavy pre-market trading.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is surging more than 30% with increasing trading activity on Thursday morning.</li>



<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are rising over 21% as it also experiences strong trading today.</li>



<li>A.k.a. Brands (NYSE:<a href="https://investorplace.com/stock-quotes/aka-stock-quote/">AKA</a>) stock is increasing 17% without any clear news this morning.</li>



<li>Orgenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgs-stock-quote/">ORGS</a>) shares are gaining more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318209149&amp;type=PDF&amp;symbol=ORGS&amp;cdn=778bdb482c018a07a4dec09546e61eb2&amp;companyName=Orgenesis+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-04-02">following recent insider buying</a>.</li>



<li>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) stock is climbing over 15% despite a lack of news on Thursday.</li>



<li>AngioDynamics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ango-stock-quote/">ANGO</a>) shares are jumping more than 15% after releasing its <a href="https://www.nasdaq.com/press-release/angiodynamics-reports-fiscal-year-2024-third-quarter-financial-results-updates-fiscal">fiscal Q3 2024 earnings report</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is getting an over 14% boost as it continues to rally on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318212492&amp;type=PDF&amp;symbol=ADXN&amp;cdn=b99f04f9c986cd5ad74a2038763835fe&amp;companyName=Addex+Therapeutics+Ltd&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-03">neurological company launch</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are up more than 13% without any clear news to report.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Casa Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/casa-stock-quote/">CASA</a>) stock is plummeting over 31% after <a href="https://www.nasdaq.com/press-release/casa-systems-initiates-court-supervised-chapter-11-sale-process-for-businesses-2024">filing for bankruptcy</a>.</li>



<li>View (NASDAQ:<a href="https://investorplace.com/stock-quotes/view-stock-quote/">VIEW</a>) stock is diving more than 29% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318216587&amp;type=PDF&amp;symbol=VIEW&amp;cdn=229f694a9f04258b182e980a2525d125&amp;companyName=View+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-04">alongside a delisting notice</a>.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) shares are tumbling over 27% on Thursday morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is taking a more than 20% beating after <a href="https://finance.yahoo.com/news/flora-growth-corp-announces-launch-003700210.html">launching a share offering</a>.</li>



<li>Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) shares are sliding over 19% alongside its <a href="https://www.nasdaq.com/press-release/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and">Q4 2023 earnings report</a>.</li>



<li>XTI Aerospace (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtia-stock-quote/">XTIA</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/04/why-is-xti-aerospace-xtia-stock-up-89-today/">after rallying yesterday</a>.</li>



<li>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) shares are declining over 13% ahead of its <a href="https://www.nasdaq.com/press-release/reliance-global-group-schedules-fourth-quarter-2023-financial-results-and-business">Q4 conference call</a>.</li>



<li>Jiuzi (NASDAQ:<a href="https://investorplace.com/stock-quotes/jzxn-stock-quote/">JZXN</a>) stock is slipping more than 13% as it continues to fall <a href="https://www.nasdaq.com/press-release/jiuzi-holdings-enters-into-a-non-binding-loi-for-the-acquisition-of-shenzhen">on acquisition plans</a>.</li>



<li>Digital Health Acqsuitiion (NASDAQ:<a href="https://investorplace.com/stock-quotes/dhac-stock-quote/">DHAC</a>) shares are dipping over 13% without any apparent news.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock closes out our pre-market stock movers down more than 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-april-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

EC, ABAT and BORR among pre-market losers

Jiuzi Holdings received Nasdaq notification letters

Jiuzi Holdings announces 1-for-13 reverse share split

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has finalized an employment agreement with Huijie Gao, appointing him as Chief F...

Jiuzi Holdings Announces New CFO and Employment Terms

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. reports a substantial increase in total assets, from $11.39 million to $56.22 mi...

Jiuzi Holdings Reports Surge in Total Assets

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings, Inc. has entered into a share purchase agreement to sell all of its 100% equity inter...

Jiuzi Holdings Announces Major Equity Sale

Jiuzi Holdings (JZXN) has released an update. Jiuzi Holdings Inc. has entered into a Securities Purchase Agreement to sell 500,000 ordinary shares ...

Jiuzi Holdings Sells Shares to International Investors

ABAT

ABIO

ACHL

ADXN

ANGO

AUVI

BORR

BROG

CADL

CASA

DHAC

DOGZ

DXYZ

EGOX

FLGC

GCTS

HSDT

HUBC

JZXN

KYCH

LGVC

LIFW

MAMO

ONMD

ORGS

RELI

REPX

TBIO

ULTA

VIEW

XTIA

ZCMD

Press Releases

Jiuzi Holdings Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

Contracts

Jiuzi Holdings Enters into a Non-Binding LOI for the Acquisition of Shenzhen Maigesong

Jiuzi Holdings Received Nasdaq Notification Letters

Jiuzi Holdings Inc. Announces 1-For-13 Reverse Share Split

Jiuzi Holdings and Shenzhen Maigesong Terminate Negotiations to Focus on Future Growth

Autozi Internet Technology (Global) Ltd. - Class A Ordinary Shares

Autozi Internet Tech

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Comments

Jiuzi Hldgs

空売り

Jiuzi Hldgs (NASDAQ:JZXN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル